BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 20863401)

  • 21. MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway.
    Jia F; Zhang Z; Zhang X
    J Cell Biochem; 2019 Apr; 120(4):6420-6430. PubMed ID: 30484892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
    Liang W; Wang F; Chen Q; Dai J; Escara-Wilke J; Keller ET; Zimmermann J; Hong N; Lu Y; Zhang J
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):1999-2012. PubMed ID: 31172267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
    Dorai T; Dutcher JP; Dempster DW; Wiernik PH
    Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone.
    Pratap J; Lian JB; Javed A; Barnes GL; van Wijnen AJ; Stein JL; Stein GS
    Cancer Metastasis Rev; 2006 Dec; 25(4):589-600. PubMed ID: 17165130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
    Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
    Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
    [No Abstract]   [Full Text] [Related]  

  • 27. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
    Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Runx2-Smad signaling impacts the progression of tumor-induced bone disease.
    Zhang X; Akech J; Browne G; Russell S; Wixted JJ; Stein JL; Stein GS; Lian JB
    Int J Cancer; 2015 Mar; 136(6):1321-32. PubMed ID: 25053011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro.
    Lin DL; Tarnowski CP; Zhang J; Dai J; Rohn E; Patel AH; Morris MD; Keller ET
    Prostate; 2001 May; 47(3):212-21. PubMed ID: 11351351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells.
    Fu Z; Dozmorov IM; Keller ET
    Prostate; 2002 Apr; 51(1):10-20. PubMed ID: 11920953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
    Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RUNX2 promotes hepatocellular carcinoma cell migration and invasion by upregulating MMP9 expression.
    Wang Q; Yu W; Huang T; Zhu Y; Huang C
    Oncol Rep; 2016 Nov; 36(5):2777-2784. PubMed ID: 27666365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.
    Özdemir BC; Hensel J; Secondini C; Wetterwald A; Schwaninger R; Fleischmann A; Raffelsberger W; Poch O; Delorenzi M; Temanni R; Mills IG; van der Pluijm G; Thalmann GN; Cecchini MG
    PLoS One; 2014; 9(12):e114530. PubMed ID: 25485970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955.
    Bisoffi M; Klima I; Gresko E; Durfee PN; Hines WC; Griffith JK; Studer UE; Thalmann GN
    J Urol; 2004 Sep; 172(3):1145-50. PubMed ID: 15311059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitric Oxide Up-Regulates RUNX2 in LNCaP Prostate Tumours: Implications for Tumour Growth In Vitro and In Vivo.
    Nesbitt H; Browne G; O'Donovan KM; Byrne NM; Worthington J; McKeown SR; McKenna DJ
    J Cell Physiol; 2016 Feb; 231(2):473-82. PubMed ID: 26189652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
    Rubin J; Chung LW; Fan X; Zhu L; Murphy TC; Nanes MS; Rosen CJ
    Prostate; 2004 Jan; 58(1):41-9. PubMed ID: 14673951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lysine Demethylase 6B Regulates Prostate Cancer Cell Proliferation by Controlling c-MYC Expression.
    Yıldırım-Buharalıoğlu G
    Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells.
    San Martin IA; Varela N; Gaete M; Villegas K; Osorio M; Tapia JC; Antonelli M; Mancilla EE; Pereira BP; Nathan SS; Lian JB; Stein JL; Stein GS; van Wijnen AJ; Galindo M
    J Cell Physiol; 2009 Dec; 221(3):560-71. PubMed ID: 19739101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TERF1 downregulation promotes the migration and invasion of the PC3 prostate cancer cell line as a target of miR‑155.
    Chen W; He LN; Liang Y; Zeng X; Wu CP; Su MQ; Cheng Y; Liu JH
    Mol Med Rep; 2020 Dec; 22(6):5209-5218. PubMed ID: 33174061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.
    Araya HF; Sepulveda H; Lizama CO; Vega OA; Jerez S; Briceño PF; Thaler R; Riester SM; Antonelli M; Salazar-Onfray F; Rodríguez JP; Moreno RD; Montecino M; Charbonneau M; Dubois CM; Stein GS; van Wijnen AJ; Galindo MA
    J Cell Biochem; 2018 Nov; 119(10):8204-8219. PubMed ID: 29923217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.